• OPEN AN ACCOUNT
Indian Indices
Nifty
24,273.80 -140.60
(-0.58%)
Sensex
79,317.16 -1,017.65
( -1.27%)
Bank Nifty
54,365.65 -245.25
( -0.45%)
Nifty IT
36,002.45 82.15
( 0.23%)
Global Indices
Nasdaq
41,380.81 245.84
(0.60%)
Dow Jones
5,684.33 32.05
(0.57%)
Hang Seng
37,492.25 563.62
(1.53%)
Nikkei 225
8,531.61 -27.72
(-0.32%)
Forex
USD-INR
84.70 0.29
(0.35%)
EUR-INR
96.08 0.41
(0.42%)
GBP-INR
112.96 0.38
(0.34%)
JPY-INR
0.59 0.00
(0.19%)

EQUITY - MARKET SCREENER

P&G to shut its injection production at Goa facility from 30 Sept
27-Sep-23   11:00 Hrs IST
?Discontinuation of production at its plant in Goa, shall not have an impact on continuity of sale of injections, as the products will be sourced from a contract manufacturer,? the company stated in press release.

The injections portfolio, procured from the company's manufacturing facility at Goa, accounted for revenue of Rs 102.92 crore during the financial year 2022-23, constituting 8.37% of the company's total revenue.

Procter & Gamble Health (P&G Health) is one of India's largest VMS companies, manufacturing and marketing vitamins, minerals, and supplements products that include Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion.

The company's net profit declined 27.6% to Rs 29.82 crore in Q4 June 2023 as against Rs 41.19 crore recorded in Q4 June 2022. Revenue from operations rose marginally to Rs 301.18 crore during the quarter from Rs 295.89 crore posted in the same period a year ago.

The counter rose 0.64% to Rs 5005 on the BSE.

Powered by Capital Market - Live News